William Blair Has Positive Estimate for APLT FY2025 Earnings

Applied Therapeutics, Inc. (NASDAQ:APLT) – Stock analysts at William Blair increased their FY2025 earnings estimates for Applied Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.66). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics’ FY2026 earnings at ($0.71) EPS.

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $1.50 price objective on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.10.

Applied Therapeutics Price Performance

APLT opened at $0.44 on Monday. Applied Therapeutics has a 1 year low of $0.30 and a 1 year high of $10.62. The company has a market capitalization of $61.66 million, a price-to-earnings ratio of -0.27 and a beta of 2.00. The firm’s fifty day moving average price is $0.43 and its two-hundred day moving average price is $1.79.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million.

Hedge Funds Weigh In On Applied Therapeutics

Several large investors have recently added to or reduced their stakes in APLT. Dark Forest Capital Management LP lifted its holdings in Applied Therapeutics by 54.5% in the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company’s stock worth $46,000 after purchasing an additional 18,949 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Applied Therapeutics by 7.5% during the fourth quarter. Nuveen Asset Management LLC now owns 281,028 shares of the company’s stock valued at $241,000 after buying an additional 19,608 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Applied Therapeutics by 169.0% in the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after buying an additional 25,601 shares in the last quarter. CreativeOne Wealth LLC boosted its position in shares of Applied Therapeutics by 132.2% during the first quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock worth $25,000 after acquiring an additional 28,701 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Applied Therapeutics by 0.7% during the fourth quarter. Deutsche Bank AG now owns 4,468,122 shares of the company’s stock worth $3,843,000 after acquiring an additional 30,520 shares during the last quarter. Hedge funds and other institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.